No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shanghai Shenqi Pharmaceutical Investment Management (600613.SH): Zhiqi No. 2 has cumulatively reduced its Shareholding by 1.25%.
Gelonghui reported on February 28 that Shanghai Shenqi Pharmaceutical Investment Management (600613.SH) announced that from December 2, 2024, to February 28, 2025, Zhiqi No. 2 reduced its shareholding in the company by 5,296,500 shares through centralized bidding, accounting for 0.99% of the total shares of the company, and reduced its shareholding by 1,380,000 shares through block trading, accounting for 0.26% of the total shares of the company; by February 28, 2025, Zhiqi No. 2 had cumulatively reduced its shareholding in the company by 6,676,500 shares, accounting for 1.25% of the company's shares. This shareholding reduction plan has reached its time Range and will end.
Optimism Around Shanghai Shenqi Pharmaceutical Investment Management (SHSE:600613) Delivering New Earnings Growth May Be Shrinking as Stock Declines 14% This Past Week
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) Stock Price Dropped 10% Last Week; Retail Investors Would Not Be Happy
shanghai shenqi pharmaceutical investment management (600613.SH): The shareholding ratio of Zhi Ji No. 2 has dropped to 4.99998%.
On December 2, Gelonhui learned that Shanghai Shenqi Pharmaceutical Investment Management (600613.SH) announced that on December 2, 2024, it received a "Simple Equity Change Report" and a "Notice of Reduction of Shares and Post-Reduction Shareholding Percentage to Below 5" issued by Zhi Ji 2. Zhi Ji 2 reduced the company's shares by 3,296,500 shares through centralized competitive trading on December 2, 2024. After this equity change, Zhi Ji 2's holding of the company's shares decreased from 30,000,000 shares to 26,703,500 shares, and the shareholding percentage decreased from 5.61722% to 4.99998%.
There May Be Some Bright Spots In Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings
More Unpleasant Surprises Could Be In Store For Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) Shares After Tumbling 26%
